Urol. praxi, 2011; 12(2): 105-110

Localized prostate cancer - diagnosis and treatment

MUDr.Michal Balík, MUDr.Miloš Broďák, Ph.D.
Urologická klinika Fakultní nemocnice v Hradci Králové

Prostate cancer (PC) is the most common solid neoplasm in Europe and USA with the third highest mortality. Introduction of PSA-based

screening multiplied incidence with stagnant level of mortality. These results can be explained by shift to lower stage at the time of

diagnosis and also by improved therapeutic schedules.

Keywords: localized prostate cancer, epidemiology, diagnostics, radical prostatectomy, radiotherapy

Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balík M, Broďák M. Localized prostate cancer - diagnosis and treatment. Urol. praxi. 2011;12(2):105-110.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Gelnarová J. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23: 311-324. Go to PubMed...
    2. Jarolím L. Trendy systémové léčby karcinomu prostaty. Urolog pro praxi 2005; 6: 62-65.
    3. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171: 1393-1401. Go to original source... Go to PubMed...
    4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246. Go to original source... Go to PubMed...
    5. Heidenreich A, Aus C, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. Go to original source... Go to PubMed...
    6. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, Schröder FH. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79-85. Go to original source... Go to PubMed...
    7. Schröder FH, Roobol MJ. Defining the optimal prostatespecific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol. 2009; 19: 227-231. Go to original source... Go to PubMed...
    8. Študent V, Grepl M, Král M, Hartmann I. Má vyšetření PSA stále význam při vyhledávání karcinomu prostaty? Urolog. pro praxi 2006; 5: 214-218.
    9. Lukeš M, Urban M, Záleský M, Zachoval R, Heráček J, Žďárský E. Prostate-specific antigen: current status. Folia Biol (Praha) 2001; 47: 41-49. Go to PubMed...
    10. Hrabec M, Študent, Grepl M. PSA velocity a její význam pro včasnou diagnostiku karcinomu prostaty Urolog. pro praxi 2008; 9: 309-312.
    11. Král M, Študent V, Kurfürstrova D, Vidlář A, Kučerová L. Gleasonovo skóre v biopsii a po radikální prostatektomii - Změny po konferenci ISUP 2005 a význam pro urologa. Urolog. pro praxi 2007; 8: 173-178.
    12. Král M, Študent V, Vidlák A, Hrabec M, Marek D. Nomogram predikce up-gradingu Gleasonova skóre v biopsii prostaty. Ces Urol 2007; 11: 82-86.
    13. Študent V, Hrabec M. Predikční nomogramy u karcinomu prostaty. Urolog. pro praxi 2008; 9: 33-36.
    14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374. Go to original source...
    15. Mašek L Hyršl L. Aktivní sledování karcinomu prostaty s nízkým rizikem - současný pohled. Urolog. pro praxi 2010; 11: 262-265.
    16. Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002; 95: 281-286. Go to original source... Go to PubMed...
    17. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-988. Go to original source... Go to PubMed...
    18. Mason MD, Warde PR, Sydes MR, et al. Intergroup randomized phase 3 study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633). Int J Radiat Oncol Biol Phys 2010; 78(Suppl 2). Go to original source...
    19. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol. 1996; 14: 2258-2265. Go to original source... Go to PubMed...
    20. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962. Go to original source... Go to PubMed...
    21. Tiguert R, Forman JD, Hussain M, et al. Radiation therapy for a rising PSA level after radical prostatectomy. Semin Urol Oncol 1999; 17: 141-147.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.